Sixty thousand people are diagnosed each year with beta-thalassaemia, requiring them to get blood transfusions for the rest of their lives.
A new gene is in clinical trials, and a recipient has not needed a transfusion for 21 months after having the gene added into his cells.
The therapy works by changing the genes in a patient's own bone marrow. The altered stem cells will not be rejected by the patient, who will now be able to produce the hemoglobin needed.
Posted by waled kalid on September 27, 2010
Add your Comment:
if you're already a member.